AZN · Pharma and healthcare · one day
AstraZeneca (AZN): news on Monday 26 October 2026
News from the 24 hours to Monday morning, 26 October 2026.
Tone of the day
What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Why it scored this way
Coverage was dominated by strong phase 3 data at ESMO, led by the experimental stomach cancer drug that doubled survival, alongside positive results for Tagrisso, Imfinzi and the Amgen combination. The tone is clearly positive, tempered slightly by a mention of a PFS miss in the ADC trial.
What drove it
- ESMO phase 3 data
- stomach cancer ADC
- Tagrisso and Imfinzi results
Around this day
| Day | Tone | Headlines |
|---|---|---|
| Tue 20 Oct | +5.5 | 24 |
| Wed 21 Oct | +8.7 | 38 |
| Thu 22 Oct | +8.3 | 28 |
| Fri 23 Oct | +8.3 | 32 |
| Sat 24 Oct | +9.2 | 8 |
| Sun 25 Oct | +10.0 | 16 |
| Mon 26 Oct | +10.0 | 33 |
6 stories · 33 headlines · strongest first
Pharma and healthcare on 26 OctoberFTSE 100 that day| Tone | What the article reported, and why it scored that way | |
|---|---|---|
| AstraZeneca stomach cancer drug sone-ve doubles survival +10.015 headlines today · Many outlets report CLARITY-Gastric01 data showing the drug doubled survival. | ||
| +10.0 | Late-stage trial showed survival twice as long. | |
| +10.0 | Positive phase 3 survival result in gastric cancer | |
| +10.0 | Doubled survival, big new franchise potential | |
| +10.0 | ADC doubles overall survival in gastric cancer | |
| +10.0 | Experimental drug doubled survival | |
| +10.0 | Experimental drug doubled survival time | |
| +10.0 | Trial shows stomach cancer treatment gave twice the survival. | |
| +10.0 | Drug extends overall survival in late-stage trial | |
| +10.0 | ADC improves survival in gastric cancer patients | |
| +10.0 | Positive phase III gastric trial results | |
| +10.0 | Drug clears survival bar in late-stage study | |
| +10.0 | Median survival doubled to 10 months | |
| +10.0 | 42% lower death risk in gastric cancer trial | |
| +8.3 | Survival data reported, share price mentioned | |
| +1.7 | Data called robust but PFS miss raises regulatory questions | |
| Tagrisso with savolitinib gives better outcomes for lung cancer driven by MET +8.57 headlines today · Outlets report SAFFRON results and plans for FDA approval. | ||
| +9.2 | Phase III Tagrisso results announced, positive | |
| +9.2 | Reduced progression and death risk in MET-driven lung cancer | |
| +8.7 | Positive PFS and OS data for Tagrisso combo | |
| +8.7 | Orpathys combo shows power after Tagrisso | |
| +8.3 | Two-pill pairing could lengthen Tagrisso's useful life against lung cancer. | |
| +8.3 | Median survival rose by close to five months with the combination. | |
| +7.5 | Pursuing FDA approval for Tagrisso combination | |
| AstraZeneca showcases cancer portfolio at ESMO +6.94 headlines today · Outlets report AstraZeneca's cancer data showcase at ESMO. | ||
| +7.5 | New targeted therapy portfolio being readied | |
| +7.5 | ESMO showcase of cancer pipeline | |
| +6.7 | Cancer drug advancing | |
| +5.8 | Data showcase at ESMO, mostly factual | |
| Imfinzi plus enfortumab vedotin cuts recurrence and death risk in bladder cancer +8.03 headlines today · 8 in all, since 25 October · Outlets report VOLGA Phase III results. | ||
| +10.0 | Imfinzi combination lowers the risk of dying from bladder cancer. | |
| +9.7 | Phase III Imfinzi results announced, positive | |
| +9.2 | Imfinzi bladder cancer reach set to expand | |
| Imfinzi and Imdelltra cut risk of dying by 58% in lung cancer of the small-cell type +10.03 headlines today · 11 in all, since 25 October · Outlets report the Amgen combination cut death risk 58%. | ||
| +10.0 | Combination reduces death risk by 58% for small cell lung tumours. | |
| +9.7 | Combo with Amgen cuts death risk in lung cancer | |
| +9.2 | Positive phase 3 combo with Imfinzi in lung cancer | |
| Akeso CEO seeks more ivonescimab combinations amid AstraZeneca investment +6.71 headline today · Fierce Pharma reports on Akeso's phase 3 win and AstraZeneca's investment. | ||
| +6.7 | Akeso partner win and AstraZeneca investment, secondary | |
Each article has its own score. The lines are our own summary; follow the source link to read the article itself.
Follow by email
A short, free morning email on how the news treated AstraZeneca: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.